azilsartan vs candesartan
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of azilsartan and candesartan. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Edarbi
Atacand
No summary available.
Candesartan is a medicine that lowers blood pressure. It can also help treat heart failure.
Information not available.
Candesartan is used to treat high blood pressure in adults and children ages 1 to 17. Lowering blood pressure reduces the risk of strokes and heart attacks. Candesartan also treats heart failure by reducing the risk of death and hospitalization.
Information not available.
Candesartan blocks a substance in your body that tightens blood vessels. This helps blood vessels relax and widens them. As a result, blood pressure is lowered and the heart can pump blood more easily.
- • Dizziness
- • Fatigue
- • Dizziness
- • Upper respiratory tract infection
- • Back pain
- • Pharyngitis (sore throat)
- • Rhinitis (runny nose)
No adverse event reports.
- Dyspnoea 3,169
- Fatigue 3,159
- Nausea 2,989
- Diarrhoea 2,764
- Dizziness 2,677
No specific warnings noted.
If you are pregnant or plan to become pregnant, stop taking this medicine right away. Candesartan can harm or cause death to your unborn baby.
No pregnancy information available.
Candesartan can cause serious harm to an unborn baby, especially during the second and third trimesters. If you are breastfeeding, talk to your doctor about whether to stop breastfeeding or stop taking this medicine.
Also Compare, Nearby Drugs
Compare azilsartan with
Compare candesartan with
How to Read This azilsartan vs candesartan Comparison
azilsartan is classified in the Angiotensin II Receptor Blocker (ARB) drug class, while candesartan sits within the Angiotensin II Receptor Blocker (ARB) class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, azilsartan has 0 submissions while candesartan has 14,758. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for azilsartan or candesartan.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.